

NeuroScientific

ASX:NSB

Next generation stem cell solution for severe Crohn's disease

Nathan Smith | Chief Executive Officer

Investor Presentation May 2026



Disclaimers

Presentation Information

This presentation has been prepared by NeuroScientific Biopharmaceuticals Ltd (ASX: NSB) based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all information necessary to make an investment decision.

This presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in NSB, nor does it constitute financial product advice or take into account any individual's investment objectives, taxation situation, financial situation or needs. An investor must not act on the basis of any matter contained in this presentation but must make its own assessment of NSB and conduct its own investigations. Before making an investment decision, investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs, and seek legal, taxation and financial advice appropriate to their jurisdiction and circumstances. NSB is not licensed to provide financial product advice in respect of its securities or any other financial products. Cooling off rights do not apply to the acquisition of NSB securities.

Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of NSB, its officers, directors, employees and agents, nor any other person, accepts any responsibility and liability for the content of this presentation including, without limitation, any liability arising from fault or negligence, for any loss arising from the use of or reliance on any of the information contained in this presentation or otherwise arising in connection with it. The information presented in this presentation is subject to change without notice and NSB does not have any responsibility or obligation to inform you of any matter arising or coming to their notice, after the date of this presentation, which may affect any matter referred to in this presentation. The distribution of this presentation may be restricted by law and you should observe any such restrictions.

Forward Looking Statements

This presentation contains certain forward-looking statements that are based on the Company's management's beliefs, assumptions and expectations and on information currently available to management. Such forward looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results or performance of NSB to be materially different from the results or performance expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding the Company's present and future business strategies and the political and economic environment in which NSB will operate in the future, which are subject to change without notice. Past performance is not necessarily a guide to future performance and no representation or warranty is made as to the likelihood of achievement or reasonableness of any forward-looking statements or other forecast. To the full extent permitted by law, NSB and its directors, officers, employees, advisers, agents and intermediaries disclaim any obligation or undertaking to release any updates or revisions to information to reflect any change in any of the information contained in this presentation (including, but not limited to, any assumptions or expectations set out in the presentation).

Company Snapshot

Corporate Share Information

As at 25 May 2026


SHARE PRICE	A\$0.09
MARKET CAPITALISATION	~A\$31.26 million

Capital Structure & Cash On Hand

	ORDINARY SHARES	PERFORMANCE SHARES	OPTIONS
CAPITAL	332.6 million	57.1 million	48.25 million
CASH	~\$5.68 million (31/3/2026)		

Share Price

As at 25 May 2026



Living with severe Crohn's Disease



“ I PLAN MY
LIFE AROUND
MY DISEASE ”



Every outing requires planning

Daily life becomes planned around access to facilities and bathrooms.



Fear of sudden flare-ups

Unpredictable symptoms create daily anxiety.



Strict diets and constant fatigue

Daily management of food triggers and living with constant lethargy.



Social isolation and anxiety

Emotional tolls can affect peoples' relationships and wellbeing.



Often ineffective or limited treatment options

For many patients, especially with severe cases, current therapies are inadequate or extremely limited.

A Large Market with Significant Unmet Need

Large patient population, rising burden, limited durable treatment options



US\$13B+

Global Crohn's
Disease market^{1,2}



6-8M

Patients with Crohn's
Disease globally^{1,2}



~30%

Become refractory
to standard
therapies³



0

Treatment options once
standard therapies fail³



A chronic condition, with
the progressive disease
burden rising



Fistulising Crohn's Disease
causes severe, life-altering
complications



Surgery often becomes
inevitable where options
are limited

We are targeting the least-served segment: patients who have exhausted current options

1. ASX Announcement (16 April 2025) – "NeuroScientific to Acquire Leading Stem Cell Technology."

2. Crohn's Disease: Dynamic Market Forecast to 2026, GlobalData. <https://www.globaldata.com/store/report/crohns-disease-dynamic-market-forecast-to-2026/>

3. ASX Announcement (19 June 2025) – "Previous StemSmart Studies Demonstrate Clinical Response"


NSB's approach to this problem

Developing a solution for the Crohn's problem



Patient focused treatment

Treatment options are extremely limited when current therapies aren't working



Strong prior clinical results

78%¹ of refractory patients showed clinical response in prior studies



Fistulising Crohn's SAS program

Real patient data from Special Access Program^{2,3,4} is guiding clinical development



Planned Phase 2 trial

Phase 2 clinical trial is anticipated in CY2026^{3,4} – a key milestone for value creation

NSB's StemSmart™ product has generated strong clinical evidence in patients with severe refractory Crohn's, providing a potential therapy where none exists currently.

1.ASX Announcement (16 April 2025) – "NeuroScientific to Acquire Leading Stem Cell Technology."

2.ASX Announcement (11 November 2025) – "NSB Progresses through Clinical Development Program with Fourth Patient Commencing Treatment Under Special Access Scheme"

3.ASX Announcement (13 January 2026) – "Successful Clinical Results Achieved under Special Access Program."

4.ASX Announcement (26 May 2026) – "Remarkable Results from Patients treated with StemSmart under the Special Access Program"

Introducing StemSmart™

NeuroScientific

Purpose-built Mesenchymal Stem Cell (MSC) therapy for patients with limited options¹



Designed for
severe inflammation

Home to inflammation sites and
modulate the immune response



Targets
treatment-resistant
patients

Developed for patients who have failed
existing biologic therapies




Proven Safe
across multiple
clinical studies

Large number of patients treated -
no serious adverse events reported



Manufactured to
regulatory standards

Produced under TGA accreditation to
ensure safety, quality and consistency



Significant Clinical Response

NeuroScientific

Demonstrated in Previous Clinical Trial with Refractory Crohn's Patients



78%

**demonstrated
clinical response*¹**

*defined as reduction in Crohn's disease
activity index (CDAI) by >100 points



44%

**achieved
remission**¹**

**defined as reduction in CDAI
score to below 150 points



Demonstrated in
prior **Phase 2
clinical study¹**




Patients treated
had **previously
failed biologics¹**



No safety events
related to treatment
with StemSmart™



Real patient data from multiple other clinical
programs **support platform approach**



StemSmart™

Special Access Program^{1,2} – StemSmart™ NeuroScientific

For Patients with Fistulising Crohn's Disease – a significant unmet medical need



4/5

patients achieved a clinical response^{3,4}
(≥50% fistula closure or discharge reduction)



Special Access Scheme

TGA program allows patients with limited treatment options access to experimental therapies¹

Fistulising Crohn's Disease

Debilitating quality of life due to abnormal tunneling between bowel and outside skin / other organs

Phase 2 insight

Real-world data is informing the planned Phase 2 clinical trial in CY2026^{3,4}

Early real-world validation in severe Crohn's patients with limited treatment options

¹ASX Announcement (7 October 2025) – "First Patients Approved for Special Access Program"

²ASX Announcement (11 November 2025) – "NSB Progresses through Clinical Development Program with Fourth Patient Commencing Treatment Under Special Access Scheme"

³ASX Announcement (13 January 2026) – "Successful Clinical Results Achieved under Special Access Program"

⁴ASX Announcement (26 May 2026) – "Remarkable Results from Patients treated with StemSmart under the Special Access Program"

Clinical Program¹

Preparations in progress for Phase 2 Clinical Trials

Fistulising Crohn's Disease



Phase 2 clinical trial in **Australia only**



Australian TGA Clinical Trial Notification pathway



Open label, single-arm study



Patient criteria & numbers in development

→ **Data intended to support Marketing
Authorisation in Australia**

Refractory Crohn's Disease



Phase 2 clinical trial in **US & Australia**



US FDA **Investigational New Drug** program



Randomised, double-blinded, 2-arm study




Patient criteria & numbers in development

→ **Data intended to support partnering for
Phase 3 and commercialisation globally**


Securing the StemSmart™ Supply Chain¹ **NeuroScientific**

Partnering with leading manufacturer for clinical & commercial scale

Patented StemSmart™ Manufacturing Process



Tech Transfer to Q-Gen Cell Therapeutics



¹ASX Announcement (31 July 2025) – "NeuroScientific Partners with Leading Biologic Manufacturer"

Strong Global IP Position & Protection

NeuroScientific

Patented manufacturing process with freedom to operate

Active Patents



- **“Cell Culture Method” for StemSmart™ technology – Dr Marian Sturm**
 - Right to Exploit with Acquisition of Isopogen Pty Ltd¹
 - Granted in 14 Markets including Australia, USA, EU, Japan, UK, China, Canada, et al
 - Patent expires in November 2034² with potential to apply for extension
 - Patented manufacturing process removes non-human proteins from cell products, improving clinical efficacy and safety



Technologies in Development



Provisional Patents Pending



12 Year US Marketing Authorisation Exclusivity Period

1. ASX Announcement (16 April 2025) – “NeuroScientific to Acquire Leading Stem Cell Technology”

2. US Patent – US9868936B2 “Cell Culture Method” (Granted 16 January 2018; Anticipated Expiry 3 November 2034) – <https://patents.google.com/patent/US9868936>

Key Milestones^{1,2,3,4}

ACHIEVED TO DATE Significant progress building a strong foundation



StemSmart™ acquisition completed

Secured patented allogeneic MSC platform and IP.



SAS Program commenced

Special Access Program for fistulising Crohn's disease initiated



Initial patients treated under SAS

First patients dosed with encouraging safety profile.



Successful clinical results achieved

Strong clinical responses observed in refractory patients.



Manufacturing partnership secured

GMP manufacturing partnership established with Q-Gen.



Clinical & Scientific Advisory Board appointed

Experienced leaders guiding clinical development strategy.



Phase 2 planning initiated

Protocol development and operational planning underway.

CURRENT POSITION Phase 2 preparation activities underway

UPCOMING MILESTONES Executing on the next phase of development



TGA Licensure at Q-Gen

StemSmart™ manufacturing fully transferred for clinical supply

2026



Regulatory submissions

Submit regulatory applications to support Phase 2 initiation.

2026



Phase 2 trial commencement

Initiate randomised Phase 2 trial in Australia and the US.

2026



Partnership discussions

Advance strategic partnerships and licensing opportunities.

2027



Expand into additional indications

Evaluate opportunities in other inflammatory conditions.

2027



Phase 3 preparation

Plan and prepare for pivotal Phase 3 development programs.

2028-2029



Commercialisation pathway

Progress activities to enable future commercial readiness.

2029-2031

1. ASX Announcement (7 October 2025) – "First Patients Approved for Special Access Program."

2. ASX Announcement (11 November 2025) – "NSB Progresses through Clinical Development Program with Fourth Patient Commencing Treatment Under Special Access Scheme."

3. ASX Announcement (13 January 2026) – "Successful Clinical Results Achieved under Special Access Program"

4. ASX Announcement (30 April 2026) – "Quarterly Activities Report for the Period Ended 31 March 2026"

Leadership & Advisory Strength¹

NeuroScientific



NATHAN SMITH

BSc
CHIEF EXECUTIVE OFFICER

25+ years in biologics and cell & gene therapies



DR MARIAN STURM

FFSc (RCPA), PhD, MSc, BSc Hons
CHIEF SCIENTIFIC OFFICER

40+ years in cellular therapy development



PROF CATHERINE COLE

MBBS, FRACP, FRCPA
CHIEF MEDICAL OFFICER

35 years in paediatric haematology, oncology & clinical trials

Board of Directors



ROB MCKENZIE

LL.B; B.Juris, FAICD
NON-EXECUTIVE CHAIRMAN

35+ years in corporate governance and M&A



DR ANTON UVAROV

PhD, MBA
NON-EXECUTIVE DIRECTOR

Neuroscience and healthcare industry specialist



PAUL FRY

BBus
NON-EXECUTIVE DIRECTOR

Public markets, capital raisings and governance expert



CLARKE BARLOW

B.Com, MAICD
NON-EXECUTIVE DIRECTOR

Capital markets adviser with biotech growth focus

Clinical & Scientific Advisory Board



DR ASHLEY IRISH

MBBS, FRACP
ADVISORY BOARD MEMBER

Renal transplant and kidney disease specialist



DR LENA THIN

MClinRes, MBBS
ADVISORY BOARD MEMBER

IBD clinician and international trial investigator



DR MICHAEL MUSK

MBBS, FRACP
ADVISORY BOARD MEMBER

Respiratory physician and lung disease expert



PROF YUBEN MOODLEY

MBBS, FRACP, MD, PhD
ADVISORY BOARD MEMBER

Pulmonary fibrosis and respiratory health leader

¹ASX Announcement (6 November 2025) – "NeuroScientific Appoints Clinical & Scientific Advisory Board"

Investment Highlights

01

Key leadership and
experience¹

02

Patented StemSmart™
Tech Platform²

03

Proven Clinical
Efficacy³

04

Commercialisation
Pathway⁴

1.ASX Announcement (6 November 2025) – “NeuroScientific Appoints Clinical & Scientific Advisory Board.”

2.ASX Announcement (16 April 2025) – “NeuroScientific to Acquire Leading Stem Cell Technology.”

3.ASX Announcement (26 May 2026) – “Remarkable Results from Patients treated with StemSmart under the Special Access Program”

4.ASX Announcement (31 July 2025) – “NeuroScientific Partners with Leading Biologic Manufacturer.”

NeuroScientific

ASX:NSB

Contact

Nathan Smith

Chief Executive Officer

+61 477 738 404

nsmith@neuroscientific.com

Dr Anton Uvarov

Founding Non-Executive Director

+61 8 6268 2641

au@neuroscientific.com